Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was explicitly designed to address this: its oligopeptide structure is far smaller than traditional neuropeptides like BDNF or NGF, and early preclinical work suggested oral administration could deliver measurable CNS effects
Angiogenesis & Matrix: Both peptides studied for capillary density/neo-vessel formation and ECM organization under injury stressors
The first injection is administered at Perfect B so the patient can learn the technique under clinical guidance
It is also banned by the World Anti-Doping Agency (WADA).
WHO-GMP certified injectable production lines Regulatory support with CTD dossier, COPP, FSC, COA, MSDS Global export to 30+ countries across Africa, Asia, CIS, and Latin America Flexible MOQ & private labeling options Fast delivery & robust cold chain logistics FAQs Q1: What is this combination used for